News

Virginia Catalyst Announces Round 15 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), announced that it is accepting letters of intent (LOI) for Grant Round 15 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.

“When you combine world class research with entrepreneurial management and capital, then stir, good things happen,” said Mike Grisham, CEO of Virginia Catalyst. “We are looking for passionate research scientists and entrepreneurial leaders in high-growth life science businesses in Virginia who could use $200,000 to $800,000 in non-dilutive grant funding to further a project that improves human health and advances economic development in the Commonwealth. Our Grant Round 15 is now open, and we strongly encourage interested parties to visit the Virginia Catalyst website and apply.”

Letters of Intent (LOI) must be received by June 20, 2023 at 5:00 PM EDT. Projects that meet funding criteria will be invited to submit a full application. Applications will be reviewed and scored by an independent review team of scientists, venture capitalists and CEOs of Virginia-based life science companies. The top eight applicant teams will be invited to present their proposal the week of September 25, 2023. Awards will be announced at the end of September 2023. The LOI submission form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.virginiacatalyst.org/apply.html).

We encourage all interested applicant teams to view our webinar that was co-hosted by Virginia Catalyst and Virginia Bio. This webinar featured an expert panel, facilitated by Mike Grisham, CEO of Virginia Catalyst, to share what it takes to score highly, get funding and position your company and research university for significant follow-on funding from large corporations, venture capitalists, DARPA, NIH and philanthropic foundations. This webinar can be viewed, and the slides downloaded on the home page of Virginia Catalyst at: https://www.virginiacatalyst.org/

Cumulatively through the first fourteen funding rounds, Virginia Catalyst has dedicated a total of $25.4 million for 53 collaborative projects. Together, these projects have created over 300 new jobs and have attracted an additional $655 million of investment capital from venture capital, private equity, corporations and government agencies including DARPA, NIH and NSF. We are proud to continue supporting research investigators and entrepreneurs in achieving value for Virginia and the nation.”

Recent News

03/21/2025

Luna Labs to Expand Research and Development Operations in Charlottesville

Governor Glenn Youngkin today announced that Luna Labs USA, LLC, a product development company accelerating breakthrough solutions to multiple industries, will invest $200,000 to expand its operations in the City of Charlottesville. The company will create 20 new jobs. “Luna Labs’ expansion demonstrates Virginia’s ability to cultivate and retain innovative technology companies,” said Governor Glenn Youngkin.

03/18/2025

Committed to Innovation: Roanoke Blacksburg Innovation Alliance Replaces Verge

The Roanoke Blacksburg Innovation Alliance, formerly Verge, unveiled a major rebrand to reflect their ongoing commitment to tech-based economic advancement and their leadership in a portfolio of organizations dedicated to developing the Roanoke Blacksburg innovation ecosystem. The elements of the Roanoke Blacksburg Innovation Alliance (RBIA) include: A new name that reflects the commitment of Roanoke Blacksburg

03/14/2025

CEL-SCI’s Head and Neck Cancer Study Clears FDA Review, Eyes Commercialization Partners

CEL-SCI Corporation announced that a third-party study published on March 6, 2025 in JAMA Oncology titled “Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial” provided data that support Multikine’s use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression